Open Access
Volume 18, Number 4, November 2011
Page(s) 333 - 336
Published online 15 November 2011
  1. Campos-Vieira N., Herrenknecht C., Vacus J., Fournet A., Bories C., Figadère B., Salmen Espindola L. & Loiseau P.M. Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomedicine and Pharmacotherapy, 2008, 62, 684–689. [CrossRef] [Google Scholar]
  2. Fakhfakh M.A., Fournet A., Prina E., Mouscadet J.F., Franck X., Hocquemiller R. & Figadere B. Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral coinfections. Bioorganic and Medicinal Chemistry, 2003, 11, 5013–5023. [CrossRef] [Google Scholar]
  3. Fournet A., Barrios A.A., Muñoz V., Hocquemiller R., Cavé A. & Bruneton J. 2-substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrobial Agents and Chemotherapy, 1993, 37, 859–863. [CrossRef] [PubMed] [Google Scholar]
  4. Fournet A., Ferreira M.E., Rojas De Arias A., Torres De Ortiz S., Fuentes S., Nakayama H., Schinini A. & Hocquemiller R. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrobial Agents and Chemotherapy, 1996, 40, 2447–2451. [PubMed] [Google Scholar]
  5. Iglarz M., Baune B., Gantier J.C., Hocquemiller R. & Farinotti R. Determination of 2-n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography. Journal of Chromatography B Biomedical Applications, 1998, 714, 335–340. [CrossRef] [Google Scholar]
  6. Mbongo N., Loiseau P.M., Billion M.A., & Robert-Gero M. Mechanism of Amphotericin B resistance in Leishmania donovani promastigotes. Antimicrobial Agents and Chemotherapy, 1998, 42, 352–357. [PubMed] [Google Scholar]
  7. Nakayama H., Loiseau P.M., Bories C., Torres De Ortoz S., Shinini A., Serna E., Rojas De Arias A., Fakhfakh M.A., Franck X., Figadère B., Hocquemiller R. & Fournet A. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and viceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4950–4956. [CrossRef] [PubMed] [Google Scholar]
  8. Nakayama H., Desrivot J., Bories C., Franck X., Figadère B., Hocquemiller R., Fournet A., Loiseau P.M. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Biomedicine and Pharmacotherapy, 2007, 61, 186–188. [CrossRef] [Google Scholar]
  9. Seifert K., Matu S., Pérez-Victoria J., Castanys S., Gamarro F. & Croft S.L. Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). International Journal of Antimicrobial Agents, 2003, 22, 380–387. [CrossRef] [PubMed] [Google Scholar]
  10. WHO – World Health Organization. Control of Leishmaniasis, Sixtieth World Health Assembly, Provisional agenda item 12.3, A60/10, 22 march 2007. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.